Cancer
Malignant Pancreatic Neoplasm
CI-CAN-00001159Explore in graph →
Top-level904 active trials8 approved drugs63 evidence items
- NCIt
- C9005
- ICD-10
- C25
- DOID
- 1793
- Other
- 1 more code
Loading cancer entity…
Loading cancer entity…
Cancer
CI-CAN-00001159Explore in graph →
Clinical trials
3,630 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (516)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05435053 | Irreversible Electroporation + Nivolumab for Patients With Metastatic Pancreatic Cancer(CHECKPOINT) | terminated | Phase 2 | 9 | Ismail GögenurOTHER | 1 | Sep 15, 2023 | clinicaltrials |
| NCT03576131 | GEN1029 (HexaBody®-DR5/DR5) Safety Trial in Patients With Malignant Solid Tumors | terminated | Phase 1 / Phase 2 | 48 | GenmabINDUSTRY | 3 | Aug 1, 2023 | clinicaltrials |
| NCT04212026 |
| Irreversible Electroporation (IRE) Followed by Nivolumab in Patients With Metastatic Pancreatic Cancer. |
| terminated |
| Phase 2 |
| 8 |
| University Hospital, Basel, SwitzerlandOTHER |
| 1 |
| Jul 18, 2023 |
| clinicaltrials |
| NCT02031536 | Everolimus in Patients With Pancreatic Neuroendocrine Tumors Metastatic to the Liver Previously Treated With Surgery | terminated | Phase 2 | 2 | ECOG-ACRIN Cancer Research GroupNETWORK | 1 | Jun 29, 2023 | clinicaltrials |
| NCT04193904 | A Study of Live Biotherapeutic Product MRx0518 With Hypofractionated Radiation Therapy in Resectable Pancreatic Cancer | terminated | Phase 1 | 13 | 4D pharma plcINDUSTRY | 1 | Jun 2, 2023 | clinicaltrials |
| NCT02376699 | Safety Study of SEA-CD40 in Cancer Patients | terminated | Phase 1 | 159 | Seagen Inc.INDUSTRY | 1 | May 1, 2023 | clinicaltrials |
| NCT03118349 | Study of 177Lu Human Monoclonal Antibody 5B1 (MVT-1075) in Combination With a Blocking Dose of MVT-5873 as Radioimmunotherapy | terminated | Phase 1 | 4 | BioNTech Research & Development, Inc.INDUSTRY | 1 | Apr 21, 2023 | clinicaltrials |
| NCT04042480 | A Study of SGN-CD228A in Advanced Solid Tumors | terminated | Phase 1 | 88 | Seagen Inc.INDUSTRY | 5 | Mar 23, 2023 | clinicaltrials |
| NCT04077372 | Assessment of a Serious Illness Conversation Guide (SICG) in Advanced Gastro-Intestinal Cancers | terminated | N/A | 12 | Stanford UniversityOTHER | 1 | Jan 27, 2023 | clinicaltrials |
| NCT03818165 | Phase 1b Study of CAR2Anti-CEA CAR-T Cell Hepatic Infusions for Pancreatic Carcinoma Patients With CEA+ Liver Metastases(AntiCEA_CART) | terminated | Phase 1 | 2 | Sorrento Therapeutics, Inc.INDUSTRY | 1 | Jan 17, 2023 | clinicaltrials |
| NCT05380557 | ARTEMIS: Study of Patients With Early Stage Pancreatic Cancer Who Have Undergone Genetic Testing(ARTEMIS) | terminated | — | 2 | Invitae CorporationINDUSTRY | 1 | Dec 7, 2022 | clinicaltrials |
| NCT04400903 | Monitoring Heart Rate Variability for the Early Detection of Pancreatic Cancer | terminated | — | 110 | OHSU Knight Cancer InstituteOTHER | 1 | Nov 22, 2022 | clinicaltrials |
| NCT04155008 | Nutrition and Pharmacological Algorithm for Oncology Patients Study | terminated | Phase 4 | 1 | Montefiore Medical CenterOTHER | 1 | Nov 16, 2022 | clinicaltrials |
| NCT03099265 | Neoadjuvant Modified FOLFIRINOX and Stereotactic Body Radiation Therapy in Borderline Resectable Pancreatic Adenocarcinoma | terminated | Phase 2 | 9 | Yale UniversityOTHER | 1 | Oct 27, 2022 | clinicaltrials |
| NCT02822716 | Irreversible Electroporation for Inoperable Hepatic and Pancreatic Malignancy(IRE) | terminated | N/A | 11 | Chinese University of Hong KongOTHER | 1 | Oct 21, 2022 | clinicaltrials |
| NCT03723915 | Pembrolizumab and Pelareorep in Treating Patients With Advanced Pancreatic Cancer | terminated | Phase 2 | 17 | Northwestern UniversityOTHER | 1 | Oct 5, 2022 | clinicaltrials |
| NCT04060342 | GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma | terminated | Phase 1 | 61 | GB006, Inc., a wholly owned subsidiary of Gossamer Bio, Inc.INDUSTRY | 2 | Aug 18, 2022 | clinicaltrials |
| NCT02681601 | Nutrition Support to Improve Outcomes in Patients With Unresectable Pancreatic Cancer | terminated | N/A | 2 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Aug 3, 2022 | clinicaltrials |
| NCT03012282 | CT Perfusion Images in Assessing Treatment Response in Patients With Pancreatic Cancer | terminated | N/A | 70 | University of WashingtonOTHER | 1 | Jul 6, 2022 | clinicaltrials |
| NCT01461915 | Phase 2 Study to Assess the Efficacy & Safety of Gemcitabine + Nab Paclitaxel With or Without Dociparstat in Metastatic Pancreatic Cancer Patients(PGPC1) | terminated | Phase 2 | 60 | Jazz PharmaceuticalsINDUSTRY | 1 | Jun 6, 2022 | clinicaltrials |
| NCT02514031 | ARQ-761 Treatment With Gemcitabine/Nab-Paclitaxel Chemotherapy In Pancreatic Cancer | terminated | Phase 1 | 17 | University of Texas Southwestern Medical CenterOTHER | 1 | Jun 3, 2022 | clinicaltrials |
| NCT04327986 | Immune Checkpoint Inhibitor M7824 and the Immunocytokine M9241 in Combination With Stereotactic Body Radiation Therapy (SBRT) in Adults With Advanced Pancreas Cancer | terminated | Phase 1 / Phase 2 | 3 | National Cancer Institute (NCI)NIH | 1 | May 18, 2022 | clinicaltrials |
| NCT04131192 | Gemcitabine and Z650 in Treating Patients With Metastatic or Recurrent Pancreatic Cancer | terminated | Phase 1 | 13 | Sunshine Lake Pharma Co., Ltd.INDUSTRY | 1 | May 6, 2022 | clinicaltrials |
| NCT03165188 | Long Term Follow-Up Study for Subjects Previously Treated With Algenpantucel-L (HyperAcute-Pancreas) Immunotherapy | terminated | — | 29 | NewLink Genetics CorporationINDUSTRY | 1 | Apr 12, 2022 | clinicaltrials |
| NCT03852836 | Evaluation of MRI Sequences for Ultra-rapid Acquisition of Bile Ducts Images(BiliFast) | terminated | N/A | 53 | IHU StrasbourgOTHER | 1 | Apr 6, 2022 | clinicaltrials |
| NCT03300921 | A Phase Ib Pharmacodynamic Study of Neoadjuvant Paricalcitol in Resectable Pancreatic Cancer A Phase Ib Pharmacodynamic Study of Neoadjuvant Paricalcitol in Resectable Pancreatic Cancer | terminated | Phase 1 | 3 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Mar 31, 2022 | clinicaltrials |
| NCT04258150 | Ipilimumab, Nivolumab, Tocilizumab and Radiation in Pretreated Patients With Advanced Pancreatic Cancer(TRIPPLE-R) | terminated | Phase 2 | 26 | Herlev HospitalOTHER | 1 | Mar 31, 2022 | clinicaltrials |
| NCT00447122 | BrUOG-PA-209: Lapatinib and Gemcitabine for Metastatic Pancreaticobiliary Cancer | terminated | Phase 1 | 25 | Brown UniversityOTHER | 1 | Mar 8, 2022 | clinicaltrials |
| NCT03784417 | EUS-guided Laser Ablation in Pancreatic Adenocarcinoma | terminated | N/A | 5 | Catholic University of the Sacred HeartOTHER | 1 | Feb 28, 2022 | clinicaltrials |
| NCT03472833 | High-dose Vitamin D3 in Pancreas Cancer(VITdCUT) | terminated | Phase 3 | 25 | Medical University of GrazOTHER | 1 | Feb 15, 2022 | clinicaltrials |
| NCT02628535 | Safety Study of MGD009 in B7-H3-expressing Tumors | terminated | Phase 1 | 67 | MacroGenicsINDUSTRY | 3 | Feb 8, 2022 | clinicaltrials |
| NCT01445327 | Predictors of Tumor Response and of Radiation Therapy Side Effects in Patients With Gastrointestinal Cancers | terminated | — | 9 | National Cancer Institute (NCI)NIH | 1 | Feb 1, 2022 | clinicaltrials |
| NCT03637491 | A Study of Avelumab, Binimetinib and Talazoparib in Patients With Locally Advanced or Metastatic RAS-mutant Solid Tumors | terminated | Phase 1 / Phase 2 | 36 | PfizerINDUSTRY | 3 | Jan 26, 2022 | clinicaltrials |
| NCT03331640 | A Health Service Research Study to Investigate Survival of Metastatic Pancreatic Cancer Patients After Sequential Chemotherapy(PANTHEON) | terminated | Phase 2 | 67 | AIO-Studien-gGmbHOTHER | 1 | Jan 11, 2022 | clinicaltrials |
| NCT03757455 | ERAS Protocol in Pancreaticoduodenectomy and Total Pancreatectomy | terminated | N/A | 35 | Tampere University HospitalOTHER | 1 | Dec 9, 2021 | clinicaltrials |
| NCT04070313 | A Phase II Study of S-1 Adjuvant Chemotherapy in Patients With Resected Pancreatic Cancer in Taiwan | terminated | Phase 2 | 36 | TTY BiopharmINDUSTRY | 1 | Dec 6, 2021 | clinicaltrials |
| NCT03407040 | Generation of Cancer Antigen-Specific T-cells From Human Induced Pluripotent Stem Cells (iPSC) for Research and Potential FutureTherapy | terminated | — | 98 | National Cancer Institute (NCI)NIH | 1 | Nov 10, 2021 | clinicaltrials |
| NCT03599362 | Study of Nivolumab, Cabiralizumab, and Stereotactic Body Radiotherapy (SBRT) for Locally Advanced Unresectable Pancreatic Cancer | terminated | Phase 2 | 7 | NYU Langone HealthOTHER | 1 | Oct 19, 2021 | clinicaltrials |
| NCT04311047 | Preoperative Detection of Lymph Node Metastases in Pancreatic and Periampullary Carcinoma Using USPIO MRI(NANO-PANC) | terminated | N/A | 26 | Radboud University Medical CenterOTHER | 1 | Sep 24, 2021 | clinicaltrials |
| NCT02687230 | Phase 1 Imaging Study of 89Zr-DFO-HuMab-5B1 With HuMab-5B1 | terminated | Phase 1 | 15 | BioNTech Research & Development, Inc.INDUSTRY | 1 | Aug 31, 2021 | clinicaltrials |
| NCT01956812 | Phase 3 Trial of 90Y-Clivatuzumab Tetraxetan & Gemcitabine vs Placebo & Gemcitabine in Metastatic Pancreatic Cancer(PANCRIT®-1) | terminated | Phase 3 | 334 | Gilead SciencesINDUSTRY | 8 | Aug 16, 2021 | clinicaltrials |
| NCT01683422 | Chemotherapy Plus Proton-chemotherapy for Locally Advanced Pancreatic Cancer | terminated | N/A | 9 | Loma Linda UniversityOTHER | 1 | Aug 10, 2021 | clinicaltrials |
| NCT01335945 | Safety and Efficacy of Cryoablation for Abdominal Pain Associated With Pancreatic Cancer | terminated | Phase 1 | 14 | Boston Scientific CorporationINDUSTRY | 1 | Jul 16, 2021 | clinicaltrials |
| NCT02908451 | A Study of AbGn-107 in Patients With Gastric, Colorectal, Pancreatic or Biliary Cancer | terminated | Phase 1 | 39 | AbGenomics B.V Taiwan BranchINDUSTRY | 2 | Jul 13, 2021 | clinicaltrials |
| NCT03451773 | M7824 (MSB0011359C) in Combination With Gemcitabine in Adults With Previously Treated Advanced Adenocarcinoma of the Pancreas | terminated | Phase 1 / Phase 2 | 7 | National Cancer Institute (NCI)NIH | 1 | Jun 16, 2021 | clinicaltrials |
| NCT02608229 | BVD-523 Plus Nab-paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Cancer | terminated | Phase 1 | 18 | Washington University School of MedicineOTHER | 1 | Apr 21, 2021 | clinicaltrials |
| NCT03137706 | Characterization of Mechanical Tissue Properties in Patients With Pancreatic, Liver, or Colon Cancer | terminated | — | 8 | University of Southern CaliforniaOTHER | 1 | Apr 5, 2021 | clinicaltrials |
| NCT02985801 | PERT for Treatment of Exocrine Pancreatic Insufficiency in Patients With Unresectable Pancreatic Cancer | terminated | Phase 1 / Phase 2 | 16 | Massimo Raimondo, M.D.OTHER | 1 | Mar 15, 2021 | clinicaltrials |
| NCT01206296 | Adjuvant Intraperitoneal Gemcitabine for Resectable Pancreatic Adenocarcinoma | terminated | Phase 2 | 9 | Medstar Health Research InstituteOTHER | 1 | Mar 9, 2021 | clinicaltrials |
| NCT00066677 | Bevacizumab With or Without Docetaxel in Treating Patients With Previously Treated Metastatic Pancreatic Cancer | terminated | Phase 2 | 32 | Fox Chase Cancer CenterOTHER | 1 | Mar 5, 2021 | clinicaltrials |
Data updated 23 days agoSource updated Sep 15, 2023source: clinicaltrials